Business Wire

Bridging the Needs of Security and Development Teams, Veracode Unveils Next-Generation Software Security Platform

4.5.2022 15:12:00 EEST | Business Wire | Press release

Share

Veracode, a leading global provider of application security testing (AST) solutions, today announced its Continuous Software Security Platform, which seamlessly embeds application security into the software development lifecycle (SDLC). The platform streamlines workflows by bringing together development and security teams to provide a broad understanding of risk, remediation guidance, and progress at every stage of the development process.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005671/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Fig. 1 The Veracode Continuous Software Security Platform (Graphic: Business Wire)

According to Veracode’s latest research, there has been a 20x increase in average scan cadence over the past decade, with most applications tested three times per week, as opposed to three times per year a decade ago. The research also showed a 31 percent increase in organizations using multiple scan types over the last three years alone.

Today, leading organizations recognize the need to leverage multiple methods to assess their software and do so across all stages of the development lifecycle. Gartner® predicts that “by 2025, 70% of organizations will consolidate the number of vendors securing the lifecycle of cloud-native applications to a maximum of three vendors.” ¹ This suggests companies are already looking for a comprehensive platform that provides flexible policy management, a holistic assessment of software risk, and integrated remediation guidance, while simplifying the complexity of managing multiple solutions.

Pervasive but Not Invasive for Developers

With increased pressure to build and deploy software at breakneck speed, development teams require security checks to be seamlessly integrated into the tools where they work so they can find and fix vulnerabilities quickly. Meanwhile, security teams must meet increasingly stringent compliance standards defined by their boards and regulatory bodies. Veracode’s Continuous Software Security Platform is pervasive but not invasive because it provides a frictionless experience for developers by embedding vulnerability analysis with remediation guidance directly into the integrated development environment.

Brian Roche, Chief Product Officer at Veracode, said, “Other vendors in our space have incomplete or disjointed solutions that lack consistent reporting and analysis, leaving customers playing a game of ‘whack a mole’ across different tools. We have continued to evolve our platform to create a seamless and integrated experience for developers, as well as provide security teams with a holistic view of their software security posture from design, through development and deployment. We see this as a win for both development and security teams that will result in the delivery of software that is more secure.”

Veracode Continuous Software Security Platform

The Veracode Continuous Software Security Platform enables users to define and manage security policy, gain a comprehensive view of software security across their application portfolio, and leverage rich analytics to make informed plans, communicate metrics, comply with policy, and meet regulatory requirements. Powered by almost two decades of data, the platform enables organizations to detect, predict, manage, and, ultimately, mitigate their security risk. These intelligent capabilities empower companies to deliver secure code at the speed and scale expected in today’s world.

The new Veracode Continuous Software Security Platform release features several new capabilities including:

  • Single-Pane-of-Glass Reporting: Security teams can now access unified reporting directly in the portal for Static Analysis, Dynamic Analysis, Software Composition Analysis, and Manual Penetration Testing. Administrators and developers now have a consolidated view into security risks, as well as flexible policy controls through stronger license management reports to address issues quickly.
  • Self-Service Peer Benchmarking: With comprehensive data and anonymized insights across all platform users, customers now have direct access to reports on the portal, which enable them to easily benchmark their DevSecOps program results against others in their industry. Tapping into many years of data and learning, customers can see how their program metrics stack up and establish plans to address their risk.
  • Software Bill of Materials (SBOM): Security teams can now generate and export SBOMs on demand with an integrated representational state transfer (REST) API. This returns data for a specific application in CycloneDX SBOM format—a standard designed for use in application security contexts and supply chain component analysis. Additionally, data from the API can be mined and transformed outside of the Veracode Platform.
  • Intelligent Remediation: The Continuous Software Security Platform will leverage technology acquired from Jaroona to detect and remediate software vulnerabilities through machine learning. Jaroona, which was recognized by Gartner Research as a “Cool Vendor” in 2021, outperforms traditional approaches by 7x to 10x in terms of accuracy, false negatives, and false positive rates, and reduces the burden on technical resources.

According to Tabrez Naqvi, Director of Information Security and Risk at Cox Automotive, “The security of our products and services is very important to us, and Veracode helps us ensure that we never lose our customers' trust and confidence."

For more information on the Veracode Continuous Software Security Platform visit https://www.veracode.com/platform.

¹Gartner, Inc. ”Predicts 2022: Consolidated Security Platforms Are the Future” by Charlie Winckless, Joerg Fritsch, Peter Firstbrook, Neil MacDonald, Brian Lowans, 1 December 2021

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

About Veracode

Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.

Learn more at www.veracode.com, on the Veracode blog and on Twitter.

Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information, please contact:
Katy Gwilliam
kgwilliam@veracode.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release

TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye